We identified that suppressor of cytokine signaling-3 (SOCS-3) gene was aberrantly methylated in its CpG island in three of 10 human hepatocellular carcinoma (HCC) cell lines. SOCS-3 RNA was undetectable in five of the 10 HCC cell lines including the three methylated cell lines, and a demethylating agent, 5-aza-2 0 -deoxycytidine, reactivated SOCS-3 expression in three cell lines tested. The DNA region where we found aberrant DNA methylation includes a signal transducers and activators of transcription (STAT) binding consensus sequence. When the DNA region was used as a promoter, DNA methylation markedly reduced promoter activity. SOCS-3 was also aberrantly methylated in six of 18 primary HCC samples. SOCS-3 expression was reduced in three of the three methylated and one of the three unmethylated primary samples examined. Restoration of SOCS-3 in cells lacking SOCS-3 expression suppressed STAT3 phosphorylation and cell growth. We found that IL-6 acted as a growth factor in HCC cells. Inhibition of SOCS-3 expression in cells whose growth was induced by IL-6 enhanced STAT3 phosphorylation and cell growth. In addition, AG490, a chemical JAK2 inhibitor, suppressed cell growth and downregulated STAT3 phosphorylation, but not FAK phosphorylation. We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells. Restoration of SOCS-3 decreased FAK phosphorylation as well as FAK protein level. Inhibition of SOCS-3 expression increased FAK phosphorylation, resulting in enhancement of cell migration. These data indicate that SOCS-3 negatively regulates cell growth and cell motility by inhibiting Janus kinase (JAK)/STAT and FAK signalings in HCC cells. Thus, loss of SOCS-3 by the associated DNA methylation confers cells advantage in growth and migration.
We identified that suppressor of cytokine signaling-3 (SOCS-3) gene was aberrantly methylated in its CpG island in three of 10 human hepatocellular carcinoma (HCC) cell lines. SOCS-3 RNA was undetectable in five of the 10 HCC cell lines including the three methylated cell lines, and a demethylating agent, 5-aza-2 0 -deoxycytidine, reactivated SOCS-3 expression in three cell lines tested. The DNA region where we found aberrant DNA methylation includes a signal transducers and activators of transcription (STAT) binding consensus sequence. When the DNA region was used as a promoter, DNA methylation markedly reduced promoter activity. SOCS-3 was also aberrantly methylated in six of 18 primary HCC samples. SOCS-3 expression was reduced in three of the three methylated and one of the three unmethylated primary samples examined. Restoration of SOCS-3 in cells lacking SOCS-3 expression suppressed STAT3 phosphorylation and cell growth. We found that IL-6 acted as a growth factor in HCC cells. Inhibition of SOCS-3 expression in cells whose growth was induced by IL-6 enhanced STAT3 phosphorylation and cell growth. In addition, AG490, a chemical JAK2 inhibitor, suppressed cell growth and downregulated STAT3 phosphorylation, but not FAK phosphorylation. We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells. Restoration of SOCS-3 decreased FAK phosphorylation as well as FAK protein level. Inhibition of SOCS-3 expression increased FAK phosphorylation, resulting in enhancement of cell migration. These data indicate that SOCS-3 negatively regulates cell growth and cell motility by inhibiting Janus kinase (JAK)/STAT and FAK signalings in HCC cells.
Introduction
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway plays a vital role in various conditions including immune reaction, cell growth and differentiation. Cytokines and growth factors bind to the membrane receptors that activate the nonreceptor tyrosine kinase, JAK. In turn, the STAT transcription factor is phosphorylated and dimerizes, resulting in transactivation of target genes (Darnell et al., 1994; Kishimoto et al., 1994; Ihle, 1996) . Suppressors of cytokine signaling (SOCS) family proteins including SOCS-3 are simultaneously activated and directly interact with JAK in normal cells. The SH2 domain of SOCS proteins is able to interact with a specific phosphorylated tyrosine residue in kinase domain of JAK molecules, resulting in the inhibition of STAT phosphorylation. Thus, SOCS proteins terminate signal transduction of cytokines and growth factors (Yoshimura et al., 1995; Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . While the SH2 domain of SOCS proteins interacts with phosphorylated tyrosine in other molecules, the SOCS box, another domain in SOCS proteins, is able to interact with Elongins B and C, and couples the SH2 domain-binding proteins to the ubiquitin-proteasome pathway (Zhang et al., 1999; Kamizono et al., 2001; Sasaki et al., 2003) . Interactions of SOCS-1 and SOCS-3 with FAK through the SH2 domains have been reported to promote polyubiquitination and subsequent degradation of FAK in COS-7 cells (Liu et al., 2003) . FAK becomes tyrosine-phosphorylated upon cell attachment to extracellular matrix proteins where integrin receptors are activated and FAK is recruited (Lipfert et al., 1992; Schaller et al., 1992) . The phosphorylation of FAK at Tyr 397 serves as a binding site for SH2 domain-containing proteins including Src kinase (Cobb et al., 1994; Schaller et al., 1994) . The FAK-Src kinase complex leads to further phosphorylation of downstream factors that control cell spreading and migration. However, a precise role of SOCS-3 in FAK signaling has not been characterized in relation to tumor progression.
Using restriction landmark genomic scanning (RLGS) analysis in which genomic NotI sites were compared between normal and hepatocellular carcinoma (HCC) samples, an aberrant NotI site, termed spot 3, has been assigned to chromosome 17 in HCC (Yoshikawa et al., 1997) . SOCS-3 has been reported to be silenced in lung cancer cells (He et al., 2003) . However, methylation-associated silencing of SOCS-3 was not characterized in HCC, and involvement of cytokines in cell growth has not been elucidated with respect to silencing of SOCS-3. Functions of SOCS-3 in the regulation of FAK have also not been analysed in human cancer, although FAK was shown to be a direct target of SOCS-3 in COS-7 cells when overexpressed (Liu et al., 2003) . In this report, we show that the SOCS-3 CpG island contains spot 3 DNA and is aberrantly methylated in HCC. SOCS-3 expression is silenced in the methylated HCC cells in which 5-aza-2 0 -deoxycytidine (5Aza-dC) is able to reactivate the expression. We further identified that in vitro methylation reduces promoter activity of a reporter plasmid containing a portion of SOCS-3 genomic DNA, which is aberrantly methylated in HCC genome. Expression of SOCS-3 downregulates both JAK/STAT and FAK activities in SOCS-3-silenced cells. Notably, endogenous SOCS-3 is able to inhibit cell growth and migration by suppressing STAT3 and FAK activities in HCC cells. We also show that IL-6 promotes growth of HCC cells, and SOCS-3 suppresses serum and IL-6-induced cell growth. Based on these findings, we propose that methylation-associated silencing of SOCS-3 results in enhanced cell growth and migration in HCC.
Results

SOCS-3 methylation and expression-silencing in HCC
We isolated spot 3 DNA using chromosome-assigned RLGS analysis (Yoshikawa et al., 1996; Yoshikawa et al., 1998) and found that the NotI site was located in SOCS-3 gene by BLAST analysis. To identify the transcription start site for human SOCS-3 gene, we performed 5 0 race analysis. SOCS-3 transcription was initiated at multiple positions between À982 and À757 relative to the translation start site as þ 1. We also found a 566 bp intron that separated exon 2 from noncoding exon 1. A dense CpG island includes the entire SOCS-3 gene composed of noncoding exon 1, intron 1 and exon 2. This is similar to the structure of murine SOCS-3 (Auernhammer et al., 1999) . Since STAT3 has been reported to transactivate SOCS-3 (Naka et al., 1997; Starr et al., 1997) , we searched the consensus STAT-binding sequence, TT(N) 5 AA, in and around SOCS-3 gene and found three in the region upstream to the translation start site (À1069 through À1061, À1046 through À1038 and À513 through À505) (Figure 1a) . We then analysed methylation of SOCS-3 gene using methylation-specific PCR (MSP) (Herman et al., 1996) . We designed three MSP primer sets around the putative STAT binding sites. The first set covers two STAT-binding sites that localize upstream to any of the identified transcription start sites. The second set spans DNA region containing three transcription start sites (the second through fourth), and the third set is able to assess DNA methylation in the region containing the third STAT-binding site (Figure 1a) . We did not find methylation with first and second primer sets in 10 HCC cell lines examined (data not shown). However, we found aberrant methylation with the third primer set in three of the 10 HCC cell lines (HuH2, Hep3B and HT17). No methylation was observed in a normal liver sample (Figure 1b) . We performed bisulfite DNA sequencing analysis in a region containing the third STAT-binding site to examine the aberrant DNA methylation in detail. We found dense DNA methylation in the genomic region from À403 through À216 in Hep3B and HuH2 cells. This region is only 100 bp away from the third STAT-binding site. Consistent with MSP data, the STAT binding site was also methylated in Hep3B and HuH2, although the methylation was not full (Figure 1c ). We next examined SOCS-3 expression status using RT-PCR. SOCS-3 expression was undetectable in five of the 10 HCC cell lines (HuH1, HuH2, Hep3B, PLC/PRF/5 and HT17), although it was found in a normal liver sample (Figure 1d ). Among the five cell lines without SOCS-3 expression, three cell lines were aberrantly methylated in SOCS-3 gene (HuH2, Hep3B and HT17), while another two cell lines were unmethylated. We tested if a DNA methylation inhibitor, 5Aza-dC, and a histone deacethylase inhibitor, trichostatin A (TSA), can reactivate SOCS-3 expression in the methylated cells. SOCS-3 expression was reactivated by 5Aza-dC in three cell lines tested (HuH1, Hep3B and HT17). In addition, the combination treatment with 5Aza-dC and TSA demonstrated a robust effect (Figure 1e ). These results indicate that SOCS-3 is silenced in association with DNA methylation. Although we did not find methylation in HuH1 cells, SOCS-3 expression was reactivated by 5Aza-dC. This can be explained by the possible methylation in another DNA region such as enhancer. We then examined whether DNA methylation affected the promoter activity of SOCS-3 gene. We cloned a DNA region where the aberrant methylation was identified, and inserted into a reporter plasmid. Using methylated or unmethylated plasmid, we measured reporter activity in HCC cells. Methylation drastically reduced promoter activity (Figure 1f) , supporting that the aberrant DNA methylation, which we found in the CpG island, is significant in SOCS-3 silencing. We next analysed SOCS-3 methylation in primary HCC samples. We found that SOCS-3 was aberrantly methylated in six of 18 samples (33.3%). In contrast, no detectable methylation was observed in any of the nontumorous liver samples examined (Figure 1g ). These results indicate that the SOCS-3 gene is methylated not only in transformed cells but also in primary HCC samples. We further examined SOCS-3 RNA expression status in the primary HCC samples using real-time PCR and found reduced SOCS-3 expression in the three methylated HCC samples examined as compared with their Promotion of growth and migration by SOCS-3 inactivation Y Niwa et al nontumorous counterparts. We also analysed three unmethylated primary HCC samples. Two HCC samples showed similar levels of RNA expression to the nontumorous counterparts, while one HCC sample showed reduced expression as compared with its' nontumorous counterpart (Figure 1h ). These findings support that DNA methylation is associated with SOCS-3 silencing. We next examined methylation status of another SOCS family gene, SOCS-1, in the HCC cell lines and primary samples (Figure 1i ). SOCS-1 is methylated in five of the 10 cell lines. Among the five methylated cell lines, three were also methylated in SOCS-3 gene (HuH2, Hep3B, and HT17). SOCS-1 was aberrantly methylated in 12 of the 18 primary HCC samples (67%). This is consistent with the reported incidence in primary HCC (Yoshikawa et al., 2001) . SOCS-3 and SOCS-1 were concomitantly methylated in five primary samples (28%). However, one sample (No. 6) was methylated in SOCS-3, but not in SOCS-1 gene. Although JAK/STAT signaling is reported to play an important role in the development of cancer, the functions of SOCS-3 have not been elucidated in HCC cells. When we exogenously expressed SOCS-3 in the Hep3B cells lacking SOCS-3 expression, tyrosine phosphorylation of STAT3 was downregulated compared with control ( Figure 2a ). The SOCS-3-restored cells demonstrated reduced growth compared with the control transfectants in colony formation assay ( Figure 2b ). This growth suppression by SOCS-3 was also observed in HuH1 cells (data not shown). To examine more about the growth suppression activity of SOCS-3, we used SOCS-3 antisense oligonucleotides to inhibit the expression of endogenous SOCS-3. When we transfected SOCS-3-expressing cells (Kim1) with SOCS-3 antisense oligonucleotides, SOCS-3 protein level was decreased in a dose-dependent manner. In contrast, transfection with sense oligonucleotides did not affect SOCS-3 protein level. Transfection with antisense oligonucleotides, but not with sense oligonucleotides, increased phosphorylation of STAT3 ( Figure 2c ). Furthermore, antisense oligonucleotides-transfected cells showed enhancement of cell growth compared with cells transfected with sense oligonucleotides or reagent alone ( Figure 2d ). We further examined growth suppression activity of SOCS-3 in cells treated with IL-6. IL-6 family cytokines are known to activate JAK/ STAT pathway, and are able to promote growth of cancer cells including myeloma (Kawano et al., 1988) and renal cell carcinoma (Miki et al., 1989) . Interestingly, the level of cell growth induced by IL-6 was similar to that by 10% serum in the majority of renal cell carcinoma cells, while cell growth induced by IL-6 was less than that by 10% serum in some renal cell carcinoma cells (Miki et al., 1989) . We incubated Kim1 cells in 10% serum-containing medium with or without IL-6. IL-6 did not promote growth as compared with IL-6-untreated cells (data not shown). Then, we reduced serum concentration from 10 to 0.5% and added IL-6 to the medium, because high concentration of serum might fully stimulate cell growth. We found that IL-6 induced cell growth in a dose-dependent manner (Figure 3a) , and tyrosine phosphorylation of STAT3 was enhanced in the IL-6-treated cells ( Figure 3b ). Next, we inhibited SOCS-3 expression using antisense oligonucleotides and treated these cells with IL-6. Again, we found antisense oligonucleotides-transfected cells promoted growth as compared with mock or sense oligonucleotides-transfected cells (Figure 3c ). IL-6-induced STAT3 phosphorylation was prolonged in antisense oligonucleotidestransfected cells ( Figure 3d ). Taken together, these results demonstrate that SOCS-3 is able to suppress cell growth by inhibiting STAT3 activity. When SOCS-3 expression was inhibited in HCC cells with antisense oligonucleotides, 10% serum-containing medium induced cell growth greater than medium containing IL-6 and 0.5% serum. This is probably because serum contains large amount of growth factors and cytokines that override the effect of supplemented IL-6 by inducing cell growth maximally.
CpG island
Inhibition of STAT3 phosphorylation and growth suppression by AG490
When a specific JAK2 inhibitor, AG490, was used in place of SOCS-3, tyrosine phosphorylation of STAT3 Three cell lines lacking SOCS-3 expression (HuH1, Hep3B and HT17) were either mock-treated, treated with 5Aza-dC alone or 5Aza-dC plus TSA. RNA expression was analysed by the RT-PCR. (f) Reporter assay. Genomic DNA region from À6 through À684 was analyzed for the promoter activity. Methylated or unmethylated promoter construct was transfected into Kim1 cells. At 24 h post-transfection, luciferase activity was measured. The values are the means of three replicates. Error bars represent standard deviations. The difference between methylated and unmethylated promoter constructs is statistically significant (Po0.001).
(g) MSP of primary HCC samples. Methylation of SOCS-3 was analysed in 18 primary HCC samples by the MSP. Six samples were paired (tumor/nontumor). In 12 residual samples, only tumor was examined. T represents a tumor sample and N represents its nontumorous counterpart. Six samples (3, 5, 6, 7, 11 and 18) showed aberrant methylation. (h) Expression of SOCS-3 mRNA in primary HCC samples. Real-time PCR analysis for SOCS-3 was performed using six paired (tumor/nontumor) HCC samples in which three were methylated (3, 5 and 6 in g) and another three were unmethylated (1, 2 and 4 in g). T represents a tumor sample and N represents its nontumorous counterpart. Values are normalized to the relative amounts of GAPDH and are the means of three replicates. Error bars represent standard deviations. The difference between N and T is statistically significant in four samples (3, 5, 6 and 4), but not in two samples (1 and 2). Three methylated and one unmethylated tumors showed reduced expression. 
Inhibition of FAK phosphorylation and suppression of cell migration by SOCS-3
While SOCS-3 negatively regulates the JAK/STAT signaling pathway, SOCS-3 is suggested to play another role in FAK-mediated signaling (Liu et al., 2003) . Consistent with the report in which FAK bound to SOCS-3 in COS-7 cells, we found that phosphorylated FAK was co-immunoprecipitated with SOCS-3 in HCC cells (Figure 5a ). SOCS-3 is reported to associate with elongins B and C complex through its SOCS box and to recruit the SH2 domain-interacting proteins to ubiquitin proteasome pathway, resulting in degradation of the proteins (Zhang et al., 1999 ). Therefore, we tested if expression of SOCS-3 affects FAK phosphorylation in the SOCS-3-inactivated HCC cells. When SOCS-3 was exogenously expressed in Hep3B cells lacking SOCS-3 expression, tyrosine phosphorylation of FAK as well as the amount of FAK protein was decreased, and the decreases accompanied an increase in polyubiquitination of FAK. Treatment of SOCS-3-transfected cells with a proteasome inhibitor, b-lactacystin, blocked the decrease in FAK protein including the phosphorylated form, and enhanced the polyubiquitination of FAK (Figure 5a ). Furthermore, blactacystin treatment increased phosphorylated FAK that was co-immunoprecipitated with SOCS-3 (Figure 5b ). We then used SOCS box-deleted construct to examine if the degradation of SOCS-3 was dependent on its SOCS box in HCC cells. The interaction of SOCS box-deleted SOCS-3 protein with FAK was maintained as the wild-type SOCS-3 bound to FAK (Figure 5c ). However, the deletion-mutant failed to interact with Elongin B, despite that the wild-type SOCS-3 did (Figure 5d ). The mutant protein was unable to increase polyubiquitination of FAK, and did not reduce phosphorylated FAK as wild type did (Figure 5c ). These findings demonstrate that SOCS-3 physically interacts with phosphorylated FAK, and the interaction mediates polyubiquitination of FAK, resulting in proteasomedependent degradation of FAK in HCC cells. The SOCS box is dispensable for the interaction between SOCS-3 and FAK, but is required for the interaction with Elongin B that appears to recruit FAK to the degradation pathway. Next, we tested this notion using endogenous SOCS-3 and FAK proteins in HCC cells. Transfection with SOCS-3 antisense oligonucleotides into Kim1 cells showed a dose-dependent decrease in SOCS-3 protein level as shown in Figure 2c , while phosphorylation of FAK was increased in a dosedependent manner. In contrast, control-sense oligonucleotides did not affect phosphorylation of FAK (Figure 5e ). This result indicates that endogenous SOCS-3 is capable of regulating phosphorylation of FAK in HCC cells. We further examined the function of SOCS-3 in FAK-mediated cell motility in HCC cells. Kim1 cells were transfected with SOCS-3 antisense oligonucleotides, and the cells attracted by fibronectin were measured. SOCS-3 antisense oligonucleotides-transfected cells demonstrated more migration compared with cells transfected with control-sense oligonucleotides (Figure 5f ). This result indicates that SOCS-3 suppresses cell motility by downregulating FAK activity in HCC cells at least in part.
Discussion
We have identified that the NotI restriction fragment, spot 3, is located in a CpG island containing SOCS-3 gene. Structural analysis demonstrates that human SOCS-3 gene is composed of noncoding exon 1, intron Furthermore, 5Aza-dC reactivated SOCS-3 expression in three cell lines tested, indicating that SOCS-3 is silenced by the associated DNA methylation. Bisulfite sequencing analysis revealed that the third STATbinding site and the adjacent region were aberrantly methylated in HCC. Significantly, methylation of this DNA region affected the promoter activity in our reporter assay. Analysis of SOCS-3 methylation in primary HCC showed aberrant methylation in six samples (33%), and SOCS-3 expression was decreased in the three methylated samples examined. This finding indicates that SOCS-3 is methylation-silenced in primary cancer as well as transformed cells. Taken together, the DNA region including the third STATbinding site appears to be crucial target for DNA methylation in HCC. We also found that SOCS-3 expression was reduced in one of the three unmethylated HCC samples examined, raising a possibility that the prevalence of SOCS-3 inactivation might be underestimated in our methylation analysis. Nevertheless, DNA methylation is strongly associated with SCOS-3-silencing, because we found that SOCS-3 expression was silenced in methylated samples, 5Aza-dC reactivated SOCS-3 expression, and methylation of the promoter construct containing the region, where we identified aberrant methylation, reduced promoter activity. Another DNA fragment, spot 7 in the RLGS analyses, has been located in SOCS-1 gene that was also methylationsilenced in HCC (Yoshikawa et al., 2001) . Methylation analysis of SOCS-3 and SOCS-1 revealed that SOCS-3 methylation was frequently observed in SOCS-1 methylated samples, suggesting that the critical involvement of SOCS family proteins in the development of cancer. Concomitant methylation was also observed in family genes such that p15 and p16 were methylated in leukemia (Herman et al., 1997) , and ASCL and ASC were methylated in HCC (Kubo et al., 2004) . SOCS-1 methylation was reported to correlate with severity of liver fibrosis (Yoshida et al., 2004 (Table 1a ). The distributions of tumor types were similar between SOCS-3-methylated and unmethylated HCC samples. We also examined fibrosis of nontumorous part of liver with respect to SOCS-3 methylation in the tumor. Among the four methylated HCC, each two samples were classified in grade 3 or 4. Among the 11 unmethylated HCC samples, two were in grade 1, and each three were in either grade 2, 3 or 4 (Table 1b) . Aberrant SOCS-3 methylation in tumor tends to accompany progressed fibrosis in the nontumorous part. Consistent with the report by Yoshida et al. (2004) , SOCS-1-methylation also correlated with severity of fibrosis in our samples (data not shown). Advanced fibrosis might accelerate the development of HCC in association with activated JAK/STAT pathway. A growing number of reports have demonstrated that the JAK/STAT signaling pathway plays a significant role in oncogenesis. A constitutively active JAK2 chimeric protein was reported in human leukemia (Lacronique et al., 1997) . Similarly, a dominant gainof-function mutant of Drosophila melanogaster JAK caused leukemia-like abnormalities (Luo et al., 1995) . The JAK2 substrate, STAT3, was constitutively activated in various cancers (Weber-Nordt et al., 1996; Garcia et al., 1997; Catlett-Falcone et al., 1999) . In addition, one of the negative regulators for JAK2, SOCS-1 that exhibited growth suppression activity, was inactivated in HCC (Yoshikawa et al., 2001) . Therefore, we investigated the consequence of SOCS-3 silencing in JAK/STAT signaling pathway. When SOCS-3 was exogenously expressed in SOCS-3-inactivated HCC cells, these cells showed decreases in STAT3 phosphorylation and colony formation efficiency. Treatment with A total of 15 primary HCC samples were analysed using Edmondson grading system. Four HCC were methylated and 11 HCC were unmethylated in SOCS-3 gene Liver fibrosis was scored using METAVIR system in 15 nontumorous parts of paired (tumor/nontumor) liver samples. Four HCC were methylated, and 11 HCC were unmethylated in the tumors Promotion of growth and migration by SOCS-3 inactivation Y Niwa et al a specific JAK2 inhibitor, AG490, also reduced STAT3 phosphorylation and cell growth. Consistent with these results, when SOCS-3 expression was inhibited by antisense oligonucleotides in cells that express endogenous SOCS-3 and were grown in medium containing either 10% serum or 0.5% serum plus IL-6, the cells showed increases in STAT3 phosphorylation and growth rate. Taken together, SOCS-3 negatively regulates growth of HCC cells by downregulating STAT activity. Growth suppression effect of SOCS-3 seems to be dependent on STAT3, but not on FAK, because AG490 reduced STAT3 phosphorylation and suppressed cell growth, despite the fact that it did not affect phosphorylation of FAK (Figure 4a) . Recently, methylation-associated silencing of SOCS-3 was reported in lung cancer, and the restoration of SOCS-3 in lung cancer cells showed growth suppression and decreased phosphorylation of STAT3 (He et al., 2003) . These data support that SOCS-3 is silenced by the associated methylation in HCC and suppresses growth of HCC cells. In addition to the inactivation of SOCS family genes, we speculate that continuous stimulations by cytokines or growth factors are required for establishing constitutively active JAK/STAT. We found that IL-6 was able to stimulate growth of HCC cells in the presence of low concentration of serum. Therefore, IL-6 appears to take part in growth of HCC cells by activating JAK/STAT pathway. Several lines of evidence support our results. IL-6 was a growth factor for hematological tumor cells such as plasmacytoma, myeloma and T-cell lymphoma cells (Kishimoto et al., 1994) . IL-6 also induced growth of solid tumor cells such that renal cell carcinoma cells grew in IL-6 supplemented medium up to a level induced by 10% serum (Miki et al., 1989 ). An in vivo experiment documented that liver grew massively in nude mice by systematic administration of IL-6 (Zimmers et al., 2003) . FAK À/À fibroblasts formed abundant focal contact sites that resulted in reduced cell motility, and overexpression or constitutive activation of FAK-enhanced cell migration (Ilic et al., 1995; Cary et al., 1996) . In metastatic and invasive colon and breast cancer, FAK expression was significantly elevated (Owens et al., 1995) . These data suggest that FAK is a key factor in cell migration and invasion. We found that SOCS-3 physically interacted with phosphorylated FAK in HCC cells. Therefore, we examined the role of SOCS-3 for FAK signaling either by exogenously expressing SOCS-3 or inhibiting endogenous SOCS-3 in HCC cells. When SOCS-3 was transfected in cells lacking SOCS-3 expression, polyubiquitination of FAK was increased, and the amount of FAK including phosphorylated form was decreased. b-Lactacystin, an inhibitor of proteolytic degradation of ubiquitinated proteins, markedly increased the polyubiquitinated FAK, resulting in increases in amount as well as phosphorylation of FAK. Significantly, b-lactacystin increased phosphorylated FAK that directly interacted with SOCS-3. SOCS-3-dependent polyubiquitination of FAK seems to be mediated by Elongin complex, because SOCS boxdeleted SOCS-3 that was unable to bind to Elongin B did not increase polyubiquitination of FAK and failed to reduce phosphorylated FAK as wild-type SOCS-3 did. Consistent with these results, inhibition of endogenous SOCS-3 expression by the antisense oligonucleotides demonstrated increase in phosphorylation of FAK in a dose-dependent manner. Furthermore, transfection of antisense oligonucleotides in HCC cells expressing endogenous SOCS-3 enhanced cell migration. Based on these data, we conclude that SOCS-3 interacts with phosphorylated FAK and downregulates FAK protein level by directing FAK to ubiquitin-proteasome pathway, resulting in reduction of cell motility in HCC cells. Exogenous coexpression of SOCS-3 and FAK showed decreases in FAK protein level and cell motility in NIH3T3 cells (Liu et al., 2003) . This supports the SOCS-3-dependent downregulations of FAK phosphorylation and cell migration that we particularly demonstrated using endogenous SOCS-3 and FAK proteins in HCC cells. We propose that methylation inactivation of SOCS-3 renders two types of advantage to cancer cells. One is to provide cells with unopposed growth stimulation through the JAK/STAT pathway, and the other is to enhance migration activity through the increased FAK signaling. Thus, methylation silencing of SOCS-3 is a crucial event in the development of HCC.
Materials and methods
Cell lines and tissue samples
Human HCC cell lines, Hep3B, HT17 and Li-7 were obtained from the cell resource center for Biomedical Research Institute of Development, Aging, and Cancer, Tohoku University. FLC4 (Nagamori et al., 2000) was a gift from Dr Seishi Nagamori. HuH1, HuH4 and HuH7 were obtained from the Japanese Culture Collection. HuH2, PLC/PRF/5 and Kim1 were gifts from the Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research. These were grown in RPMI 1640 supplemented with 10% fetal bovine serum. Primary HCC samples and adjacent normal liver tissues were obtained from patients who provided informed consent for the use of the specimens at The Cancer Institute Hospital, Japanese Foundation for Cancer Research. These tissues were frozen at À801C until use or fixed in formalin.
Race analysis
5
0 Race analysis was performed using first choice race-ready cDNA (Ambion), according to the company's protocol. The liver cDNA was used for nested amplification of SOCS-3 5 0 end. The SOCS-3-specific primers were GAAACTTGCTG TGGGTGACCAT (for the first PCR) and ACGGAGC CAGCGTGGATCTGCGCG (for the second PCR). Amplified PCR products were cloned into pCR2.1 vector (Invitrogen), and 10 clones were randomly selected and sequenced.
MSP and bisulfite sequencing analyses
MSP was carried out as described (Herman et al., 1996) . A normal liver DNA sample was purchased from Biochain Institute, Inc. Sequences of methylation-specific SOCS-3 primers around the third STAT-binding site were GGAGATTTTAGGTTTTCGGAATATTTC (forward primer) and CCCCCGAAACTACCTAAACGCCG (reverse primer), corresponding to À525 through À499 and À384 through À406, respectively. Sequences of the unmethylation-specific primers were GTTGGAGATTTTAGGTTTTTGGAATATTTT (forward primer) and AAACCCCCAAAACTACCTAAACACCA (reverse primer). Sequencers of two other MSP primer sets for SOCS-3 are available upon regent. The primer sequences for bisulfite sequencing analysis of SOCS-3 was forward (GATTY-GAGGGGGTTTAGTTTTAAGGA (Y means C or T), corresponding to À704 through À679) and reverse (CCACTACCCC AAAAACCCTCTCCTAA, corresponding to À186 through À211). MSP analysis of SOCS-1 was carried out as described (Yoshikawa et al., 2001) .
RT-PCR analysis
Total RNA was prepared using RNeasy Mini Kit (Qiagen). A normal liver total RNA sample was purchased from Stratagene. cDNA was generated by reverse transcription of 3 mg of total RNA using Superscript Preamplification System (Invitrogen). PCR for SOCS-3 was performed using 2 ml of reversetranscribed reaction mix with Taq polymerase (Takara). The primer sequences were CAAGGACGGAGACTTCGATT and GACTGGGTCTTGACGCTGA. The condition for amplification was at 32 cycles of 941C for 40 s, 601C for 40 s and 721C for 1 min. The PCR for GAPDH was performed in the same manner as the SOCS-3 amplification, except that 1 ml reversetranscribed reaction mix was used at 25 cycles of PCR. For the reactivation study, cells were treated with 1 mM 5Az-dC alone for 4 days or with 1 mM 5Az-dC for 4 days and 300 nM TSA for the last 1 day. RNA was extracted and cDNA was synthesized as described above. Real-time PCR was performed with SYBR Green PCR Master Mix (Applied Biosystems) and an ABI PRISM 7000 Sequence Detection System (Applied Biosystems), using the relative standard curve method. cDNA was amplified using either the SOCS-3-specific primer set (CAAG GACGGAGACTTCGATT and ACGGAGCCAGCGTG GATCTGCGCG) or the GAPDH primer set (CACCCA CTCCTCCACCTTT and TCCACCACCCTGTTGCTGT AG) in a 20 ml reaction mixture. Values were normalized to the relative amounts of GAPDH.
Construction of expression vector
A full-length SOCS-3 cDNA was isolated from human liver RNA (BD Biosciences) by PCR with the primer set GCTGGCTCCGTGCGCCATGGTCA and CCATGCCC TTTGCGCCCTTTAC. The PCR product was cloned into pCR2.1 vector (Invitrogen). The full-length SOCS-3 cDNA was cut out from the recombinant plasmid with EcoRI and inserted into EcoRI-digested pcDNA3.1/HisC vector (Invitrogen). A clone, pcDNA-SOCS-3, showed an in-frame ligation with the sense orientation and a correct sequence. For SOCS box-deleted construct, SH2 domain of SOCS-3 was amplified using a primer set (GCTGGCTCCGTGCGCCATGGTCA and GTAGATGTAATAGGCTCTTATG), and inserted into pcDNA3.1/HisC vector (Invitrogen).
Transfection experiments
To exogenously express SOCS-3 for protein analysis, Hep3B cells (50-70% confluence) were transfected with either SOCS-3 or backbone pcDNA3.1 vector (3 mg) using Lipofectamin plus reagents (Invitrogen), according to the company's protocol. To inhibit endogenous SOCS-3 expression, antisense oligonucleotides (5 0 -AAC TTG CTG TGG GTG ACC AT-3 0 ) at a concentration of 300 or 600 nM was transfected into Kim1 cells (30-50% confluence) in six-well plate using oligofectamin (Invitrogen), according to the company's protocol, and sense oligonucleotides (5 0 -ATG GTC ACC CAC AGC AAG TT-3 0 ) was used as control.
Reporter assay
DNA fragment from À6 through À684 was amplified by PCR and inserted into pGL3 vector (Promega). The plasmid was methylated with SssI methylase (New England Biolabs) for methylated promoter construct. The methylated or unmethylated plasmid was transfected into Kim1 cells and luciferase activity was measured at 24 h post-transfection using Dualluciferase reporter assay system (Promega).
Western blot analysis
Western blot analysis was carried out essentially as described (Yoshikawa et al., 2001) . The following antibodies were used as primary antibodies; anti-Xpress (Invitrogen), anti-SOCS-3, anti-FAK, anti-Elongin B (Santa Cruz Biotechnology), antipY397-FAK (Biosource), anti-STAT-3, anti-pY705 STAT-3 (Cell Signaling Technology), anti-alpha-tubulin (Sigma) and anti-Ubiquitin (Zymed) antibodies. To analyse STAT3 phosphorylation in transfected cells, the cells were lysed at 48 h post-transfection, and the lysates were subjected to SDS-PAGE followed by Western blotting analysis. To analsze STAT3 tyrosine phosphorylation in the presence of AG490, cells were treated with AG490 at a concentration of 50 mM for 0, 3 or 6 h. When studying FAK phosphorylation, mock, antisense or sense oligonucleotides-transfected cells were incubated with RPMI-1640 with 10% FCS. After 48 h, the cells were serum starved for 2 h, detached from the plates, and suspended in RPMI-1640 supplemented with 25 mM HEPES and 0.5% bovine serum albumin (BSA). Cells were kept in suspension for 30 min and then replated on fibronectin-coated six-well plate (Becton Dickinson) for 2 h, lysed and subjected to SDS-PAGE followed by Western blotting. To analyse ubiquitination, transfected cells were incubated with RPMI-1640 supplemented with 0.5% BSA for 24 h, treated with 25 mM of b-lactacystin (Calbiochem) for 6 h, and subjected to Western blot analysis. For immunoprecipitation study, cell lysates were cleared by centrifugation, preincubated with agarose beads alone, and then incubated with anti-Xpress or anti-FAK antibody coupled protein A/G agarose beads for several hours at 41C with rotating. The samples were washed several times, denatured, and subjected to SDS-PAGE followed by Western blotting.
Growth assay
For colony formation study, cells (30 Â 10 4 ) were transfected with either pcDNA-SOCS-3 or backbone pcDNA3.1 vector (5 mg) and selected with G418 (500 mg/ml). Colonies were stained and counted at 4 weeks post-transfection. For cell growth analysis in complete medium, transfected cells were incubated with medium containing 10% FCS after 3 h of the transfection. Cell numbers were counted by hemacytometer at 48 h post-transfection. For growth analysis of cells treated with IL-6 (R&D systems), cells (10 Â 10 4 ) were serum starved for 24 h, and incubated with various concentrations of IL-6 in the presence of 0.5% serum for 72 h before counting cell numbers. When oligonucleotides-transfected cells were used for IL-6 treatment, serum-starved cells (40 Â 10 4 ) were transfected with oligonucleotides (300 nM), and incubated with medium with 0.5% serum after 3 h of the transfection. Then, IL-6 (200 ng/ ml) was added to the medium at 24 h post-transfection, and cell numbers were counted after 72 h of IL-6 treatment. We Promotion of growth and migration by SOCS-3 inactivation Y Niwa et al used oligonucleotides at a concentration of 300 nM, because cells were sensitive to the higher concentration of oligonucleotides, when grown in medium containing 0.5% serum. For cell growth inhibition analysis with 50 mM of AG490, cells (2 Â 10 4 cells) were treated with AG490 for 5 days, and cell numbers were counted by hemacytometer.
Cell migration assay
To analyse chemotactic cell migration, cells were transfected with the antisense or sense oligonucleotides. At 48 h posttransfection, the cells were detached and kept suspended in RPMI-1640 supplemented with 25 mM HEPES and 0.5% BSA for 30 min. Then, the cells (5 Â 10 5 ) were seeded on 8 mm pore size cell culture insert. The cells were allowed to migrate against to the medium containing fibronectin (1 mg/ml) in bottom chamber for 2 h at 371C. The remnant cells on the upper membrane surface were removed with a cotton tip, and the migrated cells to the bottom surface of the membrane were fixed with 4% paraformaldehyde and stained with hematoxylin-eosin solution. The number of migrated cells was counted in the randomly selected six fields under microscopic observation.
Abbreviations JAK, Janus kinase; STAT, signal transducers and activators of transcription; SOCS, suppressors of cytokine signaling; HCC, hepatocellular carcinoma; FAK, focal adhesion kinase; RLGS, restriction landmark genomic scanning; MSP, methylationspecific PCR; 5Aza-dC, 5-aza-2 0 -deoxycytidine; TSA, trichostatin A.
